News Focus
News Focus
Followers 52
Posts 14374
Boards Moderated 0
Alias Born 06/15/2014

Re: Tseven post# 447101

Tuesday, 03/31/2026 11:49:50 AM

Tuesday, March 31, 2026 11:49:50 AM

Post# of 447908
Unless it was just consumption for the SC case, the Amarin brief basically gave the other Generics a get out of jail free card by stating that they never sued them because they did not do anything to cause the infringement. So they will just fill any void left by Hikma if they were to lose. I have only heard of one other eventuality that might accomplish eliminating all Generics and that would be if the label were invalidated as being a partial label, but honestly I am not betting any of my money on that, if and until, I see Amarin's lawyers pursuing that angle in the district court case.

Heck I am even one that worries that a new formulation does not even do that totally. I know I have been educated about the lower cost of API to Amarin for a one or two a day formulation, and how insurers will all cover the new formulation, and that there won't be patients, docs, and PBMs subbing with old IPE. But I am from Missouri and will have to see it before I totally believe it. What I do believe is the new formulation gives Amarin a better chance than just winning against one Generic company.

Really need to get Europe moving but no DTC so that does not seem to be in the cards, especially without Germany and France.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News